AT-752 targets multiple sites and activities on the Dengue virus replication enzyme NS5

Antiviral Res. 2023 Apr:212:105574. doi: 10.1016/j.antiviral.2023.105574. Epub 2023 Mar 9.

Abstract

AT-752 is a guanosine analogue prodrug active against dengue virus (DENV). In infected cells, it is metabolized into 2'-methyl-2'-fluoro guanosine 5'-triphosphate (AT-9010) which inhibits RNA synthesis in acting as a RNA chain terminator. Here we show that AT-9010 has several modes of action on DENV full-length NS5. AT-9010 does not inhibit the primer pppApG synthesis step significantly. However, AT-9010 targets two NS5-associated enzyme activities, the RNA 2'-O-MTase and the RNA-dependent RNA polymerase (RdRp) at its RNA elongation step. Crystal structure and RNA methyltransferase (MTase) activities of the DENV 2 MTase domain in complex with AT-9010 at 1.97 Å resolution shows the latter bound to the GTP/RNA-cap binding site, accounting for the observed inhibition of 2'-O but not N7-methylation activity. AT-9010 is discriminated ∼10 to 14-fold against GTP at the NS5 active site of all four DENV1-4 NS5 RdRps, arguing for significant inhibition through viral RNA synthesis termination. In Huh-7 cells, DENV1-4 are equally sensitive to AT-281, the free base of AT-752 (EC50 ≈ 0.50 μM), suggesting broad spectrum antiviral properties of AT-752 against flaviviruses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dengue Virus* / physiology
  • Dengue* / drug therapy
  • Guanosine / metabolism
  • Guanosine / pharmacology
  • Guanosine Triphosphate / metabolism
  • Humans
  • RNA, Viral / metabolism
  • Viral Nonstructural Proteins / genetics
  • Virus Replication

Substances

  • Guanosine
  • Guanosine Triphosphate
  • RNA, Viral
  • Viral Nonstructural Proteins
  • AT-752